METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to tame tough prostate cancer
Disease control OngoingThis phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail targets tough prostate cancer
Disease control OngoingThis study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…
Matched conditions: METASTATIC PROSTATE NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: Andrew J. Armstrong, MD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC